GenScript Launches CHO-Based Glutamine Synthetase Bioproduction Cell Line Service

Produced in partnership with and licensed from Horizon Discovery Group, service promotes innovation and makes biotherapeutics manufacturing

​​​GenScript, the number one global provider of gene synthesis services and a leading provider of life sciences services and products, announced the launch of a new genetically-engineered Chinese Hamster Ovary (CHO) cell line based on Glutamine Synthetase selection and licensed for commercial use. The parental cell line was developed by Horizon Discovery Group using its proprietary gene-editing technology, and adapted for commercial use by Horizon Discovery and GenScript.

“Biologics represents a major share of the global therapeutics market but their manufacturing can be cost-prohibitive due to restrictive licensing terms associated with cell line use,” said Daniel Wang, Assistant Vice President of Operations, Reagent Service Business Unit, GenScript. “GenScript’s customers can now access bioproduction-validated CHO cell lines with no royalties, no IP burden, and no licensing restrictions. We believe this arrangement will promote innovation and drive down costs associated with biotherapeutics manufacturing.”

In addition to its cell line services, GenScript offers a comprehensive portfolio of services to support protein and antibody drug discovery work, including recombinant protein expression, high-throughput antibody production, bispecific antibody production, antibody sequencing, humanization services, and more. For more information on GenScript’s cell line services, click here.

About GenScript - GenScript is the world leader in gene synthesis, and a peptide, protein, and antibody research partner for fundamental life science research, translational biomedical research, early stage biopharmaceutical development, and synthetic biology. Since its founding in 2002, GenScript has provided services and products to scientists in more than 100 countries worldwide. The company delivers biological research services encompassing gene synthesis and molecular biology, peptide synthesis, custom antibodies, protein expression, antibody and protein engineering, in vitro and in vivo pharmacology and industrial synthetic biology products. For more information, visit

TWEET THIS: @GenScript launches new, bioproduction-validated CHO-based glutamine synthetase cell line service for commercial use #BPIconf

Forward-Looking Statement Disclaimer: This press release contains forward-looking statements, including, without limitation, statements related to the earnings and sales forecasts. These forward-looking statements are based upon GenScript’s current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: market condition, global stability, new technologies.  The forward-looking statements made in this press release speak only as of the date of this press release. GenScript expressly disclaims any duty, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in GenScript’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

For More Information Contact

Corporate Contact:

Sally Wang, Chief Operating Officer
732.885.9188 ext 111

Media Contact:

Karl Schmieder

Source: GenScript